Interpace Biosciences, Inc. (IDXG)
1.08
-0.02
(-1.82%)
USD |
OTCM |
Jan 08, 11:44
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 4.783M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -53.78% |
| Valuation | |
| PE Ratio | 4.015 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 0.4137 |
| Price to Book Value | -- |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -7.584 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 97.78% |
Profile
| Interpace Biosciences, Inc. engages in the development and sale of diagnostic clinical and pharma services. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test, ThyGenX, an expanded oncogenic mutation panel that helps identify malignant thyroid nodules, ThyraMIR, which assesses thyroid nodules for risk of malignancy, and RespriDx, a genomic test that helps physicians differentiate metastatic or recurrent lung cancer. The company was founded by John P. Dugan in 1986 and is headquartered in Parsippany, NJ. |
| URL | http://www.interpacediagnostics.com |
| Investor Relations URL | http://phx.corporate-ir.net/phoenix.zhtml?c=73639&p=irol-irhome |
| HQ State/Province | New Jersey |
| Sector | Health Care |
| Industry | Health Care Providers & Services |
| Next Earnings Release | N/A |
| Last Earnings Release | Nov. 10, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| Interpace Biosciences, Inc. engages in the development and sale of diagnostic clinical and pharma services. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test, ThyGenX, an expanded oncogenic mutation panel that helps identify malignant thyroid nodules, ThyraMIR, which assesses thyroid nodules for risk of malignancy, and RespriDx, a genomic test that helps physicians differentiate metastatic or recurrent lung cancer. The company was founded by John P. Dugan in 1986 and is headquartered in Parsippany, NJ. |
| URL | http://www.interpacediagnostics.com |
| Investor Relations URL | http://phx.corporate-ir.net/phoenix.zhtml?c=73639&p=irol-irhome |
| HQ State/Province | New Jersey |
| Sector | Health Care |
| Industry | Health Care Providers & Services |
| Next Earnings Release | N/A |
| Last Earnings Release | Nov. 10, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |